• 1
    Miki Y, Swensen J, Shattuck-Eidens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994: 266 (5182): 6671.
  • 2
    Futreal PA, Liu Q, Shattuck-Eidens D et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994: 266 (5182): 120122.
  • 3
    Wooster R, Neuhausen SL, Mangion J et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994: 265 (5181): 20882090.
  • 4
    Kesselheim AS, Cook-Deegan RM, Winickoff DE, Mello MM. Gene patenting – the Supreme Court finally speaks. N Engl J Med 2013: 369 (9): 869875.
  • 5
    Warner E, Foulkes W, Goodwin P et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 1999: 91 (14): 12411247.
  • 6
    Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007: 25 (11): 13291333.
  • 7
    Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003: 72 (5): 11171130.
  • 8
    Mavaddat N, Peock S, Frost D et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst 2013: 105 (11): 812822.
  • 9
    Metcalfe K, Lubinski J, Lynch HT et al. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations. J Natl Cancer Inst 2010: 102 (24): 18741878.
  • 10
    Ozcelik H, Schmocker B, Di Nicola N et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients [letter]. Nat Genet 1997: 16 (1): 1718.
  • 11
    van Asperen CJ, Brohet RM, Meijers-Heijboer EJ et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005: 42 (9): 711719.
  • 12
    Stadler ZK, Salo-Mullen E, Patil SM et al. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer 2012: 118 (2): 493499.
  • 13
    Iqbal J, Ragone A, Lubinski J et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 2012: 107 (12): 20052009.
  • 14
    Couch FJ, Johnson MR, Rabe KG et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2007: 16 (2): 342346.
  • 15
    Hahn SA, Greenhalf B, Ellis I et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003: 95 (3): 214221.
  • 16
    Sonnenblick A, Kadouri L, Appelbaum L et al. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy. Cancer Biol Ther 2011: 12 (3): 165168.
  • 17
    James E, Waldron-Lynch MG, Saif MW. Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin a case report and review of literature. Anticancer Drugs 2009: 20 (7): 634638.
  • 18
    Kote-Jarai Z, Leongamornlert D, Saunders E et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer 2011: 105 (8): 12301234.
  • 19
    Narod SA, Neuhausen S, Vichodez G et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 2008: 99 (2): 371374.
  • 20
    Castro E, Goh C, Olmos D et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J Clin Oncol 2013: 31 (14): 17481757.
  • 21
    Tryggvadottir L, Vidarsdottir L, Thorgeirsson T et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007: 99 (12): 929935.
  • 22
    Taherian N, Hamel N, Begin LR et al. Familial prostate cancer: the damage done and lessons learnt. Nat Rev Urol 2013: 10 (2): 116122.
  • 23
    Mitra AV, Bancroft EK, Barbachano Y et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int 2011: 107 (1): 2839.
  • 24
    Kuhl CK, Schmutzler RK, Leutner CC et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 2000: 215 (1): 267279.
  • 25
    Warner E, Plewes DB, Hill KA et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004: 292 (11): 13171325.
  • 26
    Kriege M, Brekelmans CT, Boetes C et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004: 351 (5): 427437.
  • 27
    Passaperuma K, Warner E, Causer PA et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer 2012: 107 (1): 2430.
  • 28
    Rijnsburger AJ, Obdeijn IM, Kaas R et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study. J Clin Oncol 2010: 28 (36): 52655273.
  • 29
    Moller P, Stormorken A, Jonsrud C et al. Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program. Breast Cancer Res Treat 2013: 139 (1): 155161.
  • 30
    Foulkes WD, Reis-Filho JS, Narod SA. Tumor size and survival in breast cancer – a reappraisal. Nat Rev Clin Oncol 2010: 7 (6): 348353.
  • 31
    Foulkes WD. Size surprise? Tumour size, nodal status, and outcome after breast cancer. Curr Oncol 2012: 19 (5): 241243.
  • 32
    Robson ME, Chappuis PO, Satagopan J et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res 2004: 6 (1): R8R17.
  • 33
    Rennert G, Bisland-Naggan S, Barnett-Griness O et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007: 357 (2): 115123.
  • 34
    Huzarski T, Byrski T, Gronwald J et al. Ten-year survival in patients with BRCA1-negative and BRCA1-positive breast cancer. J Clin Oncol 2013: 31 (26): 31913196.
  • 35
    Chappuis PO, Goffin J, Wong N et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 2002: 39 (8): 608610.
  • 36
    Warner E, Trudeau M, Holloway C. Sensitivity of BRCA-1-related breast cancer to neoadjuvant chemotherapy: practical implications. Breast J 2003: 9 (6): 507508.
  • 37
    Silver DP, Richardson AL, Eklund AC et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010: 28 (7): 11451153.
  • 38
    Arun B, Bayraktar S, Liu DD et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers a single-institution experience. J Clin Oncol 2011: 29 (28): 37393746.
  • 39
    Byrski T, Gronwald J, Huzarski T et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010: 28 (3): 375379.
  • 40
    Byrski T, Huzarski T, Dent R et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2008: 115 (2): 35963.
  • 41
    Byrski T, Dent R, Blecharz P et al. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012: 14 (4): R110.
  • 42
    Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009: 361 (2): 123134.
  • 43
    Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer a proof-of-concept trial. Lancet 2010: 376 (9737): 235244.
  • 44
    Dubeau L. The cell of origin of ovarian epithelial tumors and the ovarian surface epithelium dogma: does the emperor have no clothes? Gynecol Oncol 1999: 72 (3): 437442.
  • 45
    Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001: 25 (10): 12831289.
  • 46
    Piek JM, van Diest PJ, Zweemer RP et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001: 195 (4): 451456.
  • 47
    Medeiros F, Muto MG, Lee Y et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006: 30 (2): 230236.
  • 48
    Crum CP, McKeon FD, Xian W. BRCA, the oviduct, and the space and time continuum of pelvic serous carcinogenesis. Int J Gynecol Cancer 2012: 22 (Suppl. 1): S29S34.
  • 49
    Folkins AK, Jarboe EA, Saleemuddin A et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol 2008: 109 (2): 168173.
  • 50
    Bijron JG, Seldenrijk CA, Zweemer RP, Lange JG, Verheijen RH, van Diest PJ. Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis. Am J Surg Pathol 2013: 37 (8): 11231130.